Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Personalized Medicine Moving to Forefront of Hematologic Malignancies

Chelsea LoCascio
Published: Friday, Nov 03, 2017

Edward A. Stadtmauer, MD

Edward A. Stadtmauer, MD
While there are still several questions unanswered surrounding chimeric antigen receptor (CAR) T-cell therapy, the recent FDA approvals of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (axi-cel; Yescarta) have led to a more promising outlook for patients with acute lymphoblastic leukemia (ALL) and non–Hodgkin lymphoma, respectively, as well as other hematologic malignancies down the line, according to Edward A. Stadtmauer, MD.

on Hematologic Malignancies, Stadtmauer, who was also chair of the event, touched upon the future of CAR T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia (AML), and remaining challenges in the multiple myeloma paradigm.

OncLive®: After 2 FDA approvals this year, what does the future hold for CAR T-cell therapy?

Stadtmauer: The first FDA approval of a new cellular therapy was for children, or young adults, with ALL. These patients who have relapsed/refractory disease have very few options. We knew from the first patients we treated how effective this therapy could be, but we had to learn a lot about the potential toxicities and how to manage [them].
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication